Brazylia - portugalski - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - analgesicos nao narcoticos

Brazylia - portugalski - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - antidiabeticos

Brazylia - portugalski - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - antiviroticos (inibe replicacao virotica)

Brazylia - portugalski - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - antidiabeticos

Unia Europejska - portugalski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod cloridrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunossupressores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Unia Europejska - portugalski - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agentes antineoplásicos - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Unia Europejska - portugalski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agentes antineoplásicos - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Brazylia - portugalski - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - luspatercepte - antianemicos

Unia Europejska - portugalski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agentes antineoplásicos - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Portugalia - portugalski - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

bristol laboratories limited - atenolol - comprimido revestido por película - 100 mg - atenolol 100 mg - atenolol - genérico - duração do tratamento: longa duração